Search
Tirzepatide Treatment Options
A collection of 110 research studies where Tirzepatide is the interventional treatment. These studies are located in the United States . Tirzepatide is used for conditions such as Obesity, Overweight and Type 2 Diabetes.
1 - 12 of 110
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Type 2 Diabetes
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
New High Blood Pressure (Hypertension) Clinical Trials
Recruiting
This campaign features 7 hypertension studies for adults with high blood pressure that remains uncontrolled despite medication. Studies are available for a range of cardiovascular profiles, including people taking multiple blood pressure medications or living with heart or vascular disease.
Inclusion Criteria:
- Diagnosed with high blood pressure (hypertension)
- Age 18+ (one study requires participants to be 55+)
- Blood pressure remains elevated despite taking medication (typically systolic 135 mmHg or higher), or your doctor has expressed concerns about your blood pressure
- Currently taking 2 or more blood pressure medications
- Have cardiovascular disease (such as a previous heart attack, coronary artery disease, stroke, or peripheral artery disease) or certain cardiovascular risk factors, including diabetes, chronic kidney disease (CKD), atrial fibrillation (AF), or smoking (study dependent)
- Stable body weight for the past 3 months
Find out if you qualify today.
Inclusion Criteria:
- Diagnosed with high blood pressure (hypertension)
- Age 18+ (one study requires participants to be 55+)
- Blood pressure remains elevated despite taking medication (typically systolic 135 mmHg or higher), or your doctor has expressed concerns about your blood pressure
- Currently taking 2 or more blood pressure medications
- Have cardiovascular disease (such as a previous heart attack, coronary artery disease, stroke, or peripheral artery disease) or certain cardiovascular risk factors, including diabetes, chronic kidney disease (CKD), atrial fibrillation (AF), or smoking (study dependent)
- Stable body weight for the past 3 months
Find out if you qualify today.
Conditions:
Hypertension Multi
Hypertension
Pulmonary Hypertension
Ocular Hypertension
Pulmonary Arterial Hypertension
Featured Trial
New Obesity Clinical Studies Now Recruiting
Recruiting
We are seeking participants for multiple clinical trials focused on obesity and metabolic health, evaluating investigational treatments for weight management and diabetes. Studies are looking for adults with obesity, with or without type 2 diabetes, who are not currently taking GLP-1 medications or other weight-loss treatments.
See if you qualify today.
See if you qualify today.
Conditions:
Obesity Multi
Obesity
Overweight and Obesity
Morbid Obesity
Childhood Obesity
Featured Trial
Multiple Type 2 Diabetes Studies Now Recruiting
Recruiting
We are seeking participants for 14 clinical studies investigating new treatments for type 2 diabetes (T2DM) and related conditions including obesity and fatty liver disease (MASH/NAFLD). Studies are looking for adults with a confirmed T2DM diagnosis who are not well-controlled or are seeking improved management, spanning a range of disease stages from early/diet-managed to long-standing and multiply medicated.
See if you qualify today.
See if you qualify today.
Conditions:
Type 2 Diabetes Multi
Type 2 Diabetes
Diabete Type 2
Diabetic Nephropathy Type 2
Type 2 Diabetes Mellitus
Featured Trial
Reduce Heart Failure Risk – See if You Qualify for a Study
Recruiting
We are currently looking for individuals aged 18 and older to take part in a heart disease research study. You may be eligible if you have been diagnosed with all of the following:
• Cardiovascular Disease
• Type 2 Diabetes
• High Blood Pressure
This study is exploring an investigational medication that may help reduce the risk of heart-related complications.
If you’re interested in learning more, you can see if you pre-qualify today.
• Cardiovascular Disease
• Type 2 Diabetes
• High Blood Pressure
This study is exploring an investigational medication that may help reduce the risk of heart-related complications.
If you’re interested in learning more, you can see if you pre-qualify today.
Conditions:
Heart Diseases
Congenital Heart Disease
Coronary Heart Disease
Ischemic Heart Disease
Heart Disease
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
Recruiting
This is a single center randomized double blind controlled study of patients (BMI\> 30 kg/m2) with obesity and Atrial Fibrillation (AFIB) randomized to Tirzepatide vs. placebo. It is expected that the significant weight loss with Tirzepatide will result in improved control, management, symptom severity, and burden of AFIB at 12 months.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/02/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Atrial Fibrillation, Obesity
Bariatric Surgery vs. Semaglutide vs. Tirzepatide
Recruiting
The recent introduction of the new generation of anti-obesity medications (AOMs) will change the future of obesity treatment. These highly effective medications, such as high-dose semaglutide and tirzepatide, are hormone analogues that augment the incretin function and exert multiple physiological effects by activating glucagon-like peptide-1 (GLP-1) and/or glucose-dependent insulinotropic polypeptide (GIP) distributed in various organs. These medications provide an average of 15-22% weight redu... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/15/2025
Locations: The Cleveland Clinic, Cleveland, Ohio
Conditions: Obesity and Obesity-related Medical Conditions
Tirzepatide in MetALD
Not Yet Recruiting
Background:
People with alcohol use disorder (AUD) often develop metabolic alcohol-associated liver disease (MetALD). MetALD is a term for the heart, liver, obesity, and other issues that can accompany AUD. MetALD can be fatal. An approved weight management drug (Tirzepatide) may be able to help people with AUD and MetALD control their alcohol intake.
Objective:
To test Tirzepatide in people with AUD and MetALD.
Eligibility:
People aged 21 years and older with AUD and MetALD.
Design:
Part... Read More
Gender:
ALL
Ages:
Between 21 years and 100 years
Trial Updated:
08/22/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Metabolic Alcohol-associated Liver Disease, Alcohol Use Disorder
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Completed
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/22/2025
Locations: University of Alabama at Birmingham Medical Center, Birmingham, Alabama +635 locations
Conditions: Type 2 Diabetes Mellitus
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
Active Not Recruiting
This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2025
Locations: Cahaba Research, Pelham, Alabama +143 locations
Conditions: Diabetes Mellitus, Type 2
Comparison of Body Composition Changes With Weight Loss Interventions
Recruiting
This study is being done to compare the effects of a newer class of weight loss medications to weight loss surgery on the body's muscle, metabolism, and side effects over time. People with severe obesity often lose weight using either medications like GLP-1 receptor agonists (such as semaglutide or tirzepatide) or by having bariatric surgery, such as gastric bypass. While both approaches can lead to weight loss, they may affect the body in different ways.
The investigators are inviting adult pa... Read More
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
08/20/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Obesity
Pre-surgical Tirzepatide-assisted Weight Loss in Men With Diabetes and Prostate Cancer: A Pilot Feasibility Study
Recruiting
The goal of this clinical research study is to determine how well a tirzepatide-assisted weight loss program works before a prostatectomy in patients with intermediate risk prostate cancer
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Conditions: Diabetes, Prostate Cancer
Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
Not Yet Recruiting
The purpose of this study is to assess the efficacy and safety of tirzepatide in adults with obesity and binge-eating disorder, comparing tirzepatide against placebo and lisdexamfetamine dimesylate. All participants will receive guided self-help cognitive behavioral therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Obesity and Overweight, Binge Eating Disorder
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
Recruiting
The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits.
Participants who have completed the primary 72-week GPIX study and have been off treatment for no more than 12 weeks (including the 4-week safety follow-up period), will have the o... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
08/15/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California +72 locations
Conditions: Obesity, Weight Gain
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
Completed
The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/15/2025
Locations: Heart Center Research, Huntsville, Alabama +145 locations
Conditions: Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults
Not Yet Recruiting
Obesity and type 2 diabetes mellitus (T2DM) represent major public health concerns in the aging community. Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist recently approved for the treatment of T2DM and obesity has been shown to be effective at reducing weight, improving markers of T2DM control, and improving cardiovascular health. Utilization of tirzepatide among older adults has been on the rise since FDA approva... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/11/2025
Locations: University of Texas Health Science Center at San Antonio, San Antonio, Texas
Conditions: Obesity Prevention, Sarcopenia in Elderly, Cardiovascular Function, GLP - 1, Weight Loss
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
Not Yet Recruiting
The primary objective of this research study is to evaluate the effect of tirzepatide, relative to placebo, as an adjunct to BUP on retention, substance use, and sleep outcomes in individuals with OUD.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Tarzana Treatment Centers, Tarzana, California +9 locations
Conditions: Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
1 - 12 of 110